Exiqon, Asuragen Ink Deal to Offer microRNA PCR-based Services | GenomeWeb

NEW YORK (GenomeWeb News) – Exiqon and Asuragen announced today the signing of a service center agreement allowing Asuragen to offer real-time PCR services based on Exiqon's miRcury LNA Universal RT-microRNA PCR products.

Exiqon's technology is used for discovering new biomarkers of diseases and biological processes and combines Universal RT reaction with LNA-enhanced PCR primers. Asuragen Genomic Services Division provides nucleic acid-based services, including biomarker discovery and companion diagnostic development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.